--- title: GKV-BStabG is now law: What changed and what to do next description: "Germany's GKV-BStabG passed on 10 July. Our full analysis of the final law: what changed in committee, what it costs, and what P&MA teams should do before January 2027." image: https://offers.accessinfinity.com/hubfs/Part%202%20White%20feat%20image%20NEW.png --- [![AI Logo White](https://offers.accessinfinity.com/hs-fs/hubfs/AI%20Logo%20White.png?width=628&height=72&name=AI%20Logo%20White.png "AI Logo White")](https://accessinfinity.com/) Inside Germany’s Evolving Access Landscape | Part 2 # GKV-BStabG is now law:  What changed and what to do next ![Part 2 Cover White Icon NEW](https://offers.accessinfinity.com/hs-fs/hubfs/Part%202%20Cover%20White%20Icon%20NEW.png?width=350&height=250&name=Part%202%20Cover%20White%20Icon%20NEW.png "Part 2 Cover White Icon NEW") ### Ten weeks from cabinet draft to law. This whitepaper provides a structured, provision-by-provision breakdown of the final law, how it differs from the April draft, and the actions your Pricing & Market Access team should be taking to prepare. Why download?  Understand exactly what changed between the April draft and the final law, provision by provision   Rebuild your revenue assumptions against the fixed 15.5% manufacturer rebate, applying in full from 1 January 2027   Identify whether your portfolio, therapy area, or lifecycle stage carries above-average exposure to the four most impactful changes   Find the exemption and supersession routes that may bring your effective rate below the 15.5% headline   Get a clear, sequenced plan your team can act on this quarter  What's inside?  Provision-by-provision analysis - What was adopted, what changed in committee since the April draft, and how it compares to our May predictions.   The four most impactful changes - The fixed rebate, the tightened volume fallback, selective tendering, and the vaccine category rebate, each on its own page   Exposure by company and product type - Which portfolios, therapy areas, and lifecycle stages face the greatest impact, and the strategic priority for each.    European price corridor guidance - Why the rebate and the supersession route affect your international reference pricing differently, and how to model the trade-off.   Portfolio decisions and calendar - A sequenced action plan across five common portfolio situations, mapped to the dates each decision falls due.    **This Resource is Essential For:** Global Pricing and Market Access leaders, Launch and Lifecycle Excellence leaders, HEOR and Evidence Strategy leads,  who need to move from the April draft to a concrete 2027 plan.   ### Download the whitepaper   ![DE reform article pages](https://offers.accessinfinity.com/hs-fs/hubfs/DE%20reform%20article%20pages.png?width=400&height=314&name=DE%20reform%20article%20pages.png "DE reform article pages") ### Have you read Part 1 of our series on Germany's evolving access landscape? Part 1 assessed the April cabinet draft: all seven provisions, and our predictions on which would pass as drafted. Read it alongside Part 2 to see how the final law diverged. [Download now](https://offers.accessinfinity.com/germanys-gkv-bstabg-reform-whitepaper) ## Check out our additional resources ![MA in IRP Feat image Final NEW](https://offers.accessinfinity.com/hs-fs/hubfs/MA%20in%20IRP%20Feat%20image%20Final%20NEW.png?width=1024&height=536&name=MA%20in%20IRP%20Feat%20image%20Final%20NEW.png "MA in IRP Feat image Final NEW") [Download Part 1 Market Access in the IRP Era](https://offers.accessinfinity.com/navigating-mfn-drug-pricing-reform) ![Analogue analysis blog scorecard](https://offers.accessinfinity.com/hs-fs/hubfs/Analogue%20analysis%20blog%20scorecard.png?width=1024&height=536&name=Analogue%20analysis%20blog%20scorecard.png "Analogue analysis blog scorecard") [Read Analogue Analysis in Rare Diseases](https://accessinfinity.com/blogs/analogue-analysis-in-rare-diseases/) ![W19 On demand Access Now Feat image](https://offers.accessinfinity.com/hs-fs/hubfs/W19%20On%20demand%20Access%20Now%20Feat%20image.png?width=1024&height=536&name=W19%20On%20demand%20Access%20Now%20Feat%20image.png "W19 On demand Access Now Feat image") [Watch 'AI in market access: Smart applications and limitations'](https://offers.accessinfinity.com/ai-in-market-access-webinar-series) Copyright © 2026 Access Infinity. All Rights Reserved.